Bridging the gap between the promise of technology and reality - Lokavant's hopes for SCOPE

24-Jan-2024 - Last updated on 24-Jan-2024 at 10:40 GMT

Andrew Mills, executive vice president of global commercial Lokavant and says the company can help businesses identify risk trends in trials much earlier than traditional methods.

He says Lokavant's solution can provide valuable insights to help streamline your trial process and ensure its success.

1.Why do you think it is important to attend SCOPE?

Much like our mission at Lokavant, SCOPE provides every major stakeholder in our industry with an opportunity to connect with other innovators and is the perfect event to collaborate on driving innovation in clinical trials. This year is uniquely important as there has been a tremendous amount of inte

rest in AI-enabled solutions, and this allows Lokavant to showcase our vision in transforming clinical research through intelligent technology.

2. What do you hope to achieve this year while you are there?

Lokavant’s goal is to continue our momentum from 2023 and showcase the real-world ways our Clinical Trial Intelligence platform is a game-changer in the industry. It provides study teams with real-time, AI-driven data insights, aiding in efficient trial design, planning, and execution. We will connect with industry leaders, potential clients, and partners to discuss collaborative opportunities at SCOPE.

3. Do you have an inkling what the buzz theme will be this year?

We believe there is still a gap between the promise of technology and reality. In 2024, the buzz around SCOPE and other industry events will be about shrinking this gap to drive tangible impact and meaningful improvements to clinical trials through pragmatic applications of AI-optimized trials.

4. For those who have never attended SCOPE before, what would you say to entice them?

It's Florida in February! From Lokavant’s HQ in NYC, Florida is about a 40 to 60-degree upgrade so that alone is worth the trip. In all seriousness, SCOPE is unique in that it brings together clinical operations leaders, not just executives or scientists or statisticians, but passionate people working on the front lines of research, interacting with patients, engaging with site staff, and working to address the real-life challenges that we all need to overcome.

5. What part of it are you looking forward to the most?

I’m looking forward to the interactive panel on Monday morning featuring use cases of generative AI in clinical research with moderator Brian Martin of AbbVie. Lokavant is also excited to showcase our Clinical Trial Intelligence Platform and latest case studies at a luncheon presentation on Monday afternoon titled: "Making rare connections in rare conditions: Forecasting study performance in rare disease with AI to help find the right patients and investigators.”